PharmaPoint: Osteoporosis - UK Drug Forecast and Market Analysis to 2022

News provided by

Apr 16, 2013, 04:26 ET

NEW YORK, April 16, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Osteoporosis - UK Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p01158416/PharmaPoint-Osteoporosis---UK-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Summary

GlobalData has released its new Country report, "PharmaPoint: Osteoporosis - UK Drug Forecast and Market Analysis to 2022". Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the 'gold-standard' bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications. Additionally, Eli Lilly's blockbuster Evista, the only available SERM in the US, will lose patent protection in 2014, flooding the market with yet more affordable generic options. Also during the forecast period covered by this report, osteoporosis drug development research will lead to the launches of a wave of novel anabolic drugs with greater efficacy and safety, causing a major market shift away from anti-resorptive drugs. The number of companies vying for patient share will shrink by as much as 50%, as established players exit the market or acquire smaller players. Lastly, the aging of the population in developed markets will result in a larger patient pool.

These changes in the osteoporosis market will be reflected in the slow growth during the forecast period, with the market growing from $6 billion to $8 billion in 2011 USD at a CAGR of 3%.

The large dip in sales caused by these expiries is offset by pipeline product launches over the forecast period, with three of these being potential blockbuster drugs. This next generation of drugs typically consists of biologics and will be higher priced than the drugs losing patent protection in the first half of the forecast period.

Scope

- Overview of the Osteoporosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the UK from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the UK Osteoporosis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Osteoporosis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in the UK

Table of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 16
3.1.3 Risk Factors 17
3.1.4 Quality of Life 17
3.2 Symptoms 18
4 Disease Management 19
4.1 Treatment Overview 19
4.1.1 Diagnosis and Referral 19
4.1.2 Treatment Guidelines 20
4.1.3 Disease Management 21
4.2 United Kingdom 24
4.2.1 Diagnosis 24
4.2.2 Clinical Practice 25
5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitor Assessment 26
5.3 Product Profiles – Major Brands 30
5.3.1 Actonel (risedronate sodium) 30
5.3.2 Evista (raloxifene hydrochloride) 33
5.3.3 Reclast (zolendronic acid) 36
5.3.4 Forteo (teriparatide) 39
5.3.5 Prolia (denosumab) 43
5.3.6 Protelos (strontium ranelate) 46
5.3.7 Miacalcin and Fortical (calcitonin-salmon) 49
5.3.8 Viviant/Conbriza (bazedoxifene) 52
5.3.9 Recalbon/Bonoteo (minodronic acid hydrate) 55
5.3.10 Alendronate sodium 57
5.3.11 Ibandronate 59
6 Opportunity and Unmet Need 60
6.1 Overview 60
6.2 Unmet Needs 60
6.2.1 Disease Awareness and Early Diagnosis 60
6.2.2 Patient Compliance 61
6.2.3 Efficacy 62
6.2.4 Safety 62
6.2.5 Treatment Cost 63
6.2.6 Earlier Intervention 63
6.3 Unmet Needs Gap Analysis 64
6.4 Opportunity 1: Dual-Action Therapies 65
6.5 Opportunity 2: Osteoporosis Prevention Therapies 66
6.6 Opportunity 3: Dosing and Administration 67
7 Pipeline Assessment 68
7.1 Overview 68
7.2 Promising Drugs in Clinical Development 69
7.2.1 Aprela (bazedoxifene and conjugated estrogens) 70
7.2.2 Romosozumab (AMG-785) 76
7.2.3 Odanacatib 81
7.2.4 BA-058 86
7.2.5 PTH(1-31)NH2 90
7.2.6 Ostora (recombinant salmon calcitonin) 94
8 Market Outlook 100
8.1 United Kingdom 100
8.1.1 Forecast 100
8.1.2 Key Events 104
8.1.3 Drivers and Barriers 104
9 Appendix 107
9.1 Bibliography 107
9.2 Abbreviations 114
9.3 Methodology 116
9.4 Forecasting Methodology 116
9.4.1 Diagnosed Osteoporosis Patients 117
9.4.2 Percent Drug-Treated Patients 117
9.4.3 Drugs Included in Each Therapeutic Class 117
9.4.4 Launch and Patent Expiry Dates 118
9.4.5 General Pricing Assumptions 119
9.4.6 Individual Drug Assumptions 119
9.4.7 Generic Erosion 124
9.4.8 Pricing of Pipeline Agents 124
9.5 Physicians and Specialists Included in this Study 125
9.5.1 About the Authors 126
9.5.2 Global Head of Healthcare 127
9.6 About GlobalData 128
9.7 Contact Us 128
9.8 Disclaimer 128

List of Tables

Table 1: Etiology of Primary Osteoporosis 13
Table 2: Etiology of Secondary Osteoporosis 15
Table 3: Symptoms of Osteoporosis 18
Table 4: Diagnostic Tests for Osteoporosis 19
Table 5: T-Score Ranges for Determination of BMD 20
Table 6: Treatment Guidelines for Osteoporosis 21
Table 7: Most Prescribed Drugs for Osteoporosis by Therapeutic Class in the Global Markets, 2012 22
Table 8: Leading Treatments for Osteoporosis, 2012 29
Table 9: Product Profile – Actonel 31
Table 10: Actonel SWOT Analysis, 2012 32
Table 11: Product Profile – Evista 34
Table 12: Evista SWOT Analysis, 2012 35
Table 13: Product Profile – Reclast 37
Table 14: Reclast SWOT Analysis, 2012 38
Table 15: Product Profile – Forteo 40
Table 16: Mean Percent Change from Baseline in BMD with Forteo vs. Placebo in Postmenopausal Women with Osteoporosis 41
Table 17: Forteo SWOT Analysis, 2012 42
Table 18: Product Profile – Prolia 43
Table 19: Prolia SWOT Analysis, 2012 45
Table 20: Product Profile – Protelos 46
Table 21: Protelos SWOT Analysis, 2012 47
Table 22: Product Profile – Miacalcin and Fortical Nasal Spray 50
Table 23: Adverse Events with Miacalcin Nasal Spray 50
Table 24: Miacalcin and Fortical Nasal Spray SWOT Analysis, 2012 51
Table 25: Product Profile – Viviant/Conbriza 53
Table 26: Viviant/Conbriza SWOT Analysis, 2012 54
Table 27: Product Profile – Recalbon/Bonoteo 55
Table 28: Recalbon/Bonoteo SWOT Analysis, 2012 56
Table 29: Overall Unmet Needs – Current Level of Attainment 60
Table 30: Clinical Unmet Needs – Gap Analysis, 2012 64
Table 31: Osteoporosis – Pipeline, 2012 69
Table 32: Comparison of Therapeutic Classes in Development for Osteoporosis, 2012 69
Table 33: Product Profile – Aprela 71
Table 34: Aprela SWOT Analysis, 2012 75
Table 35: Product Profile – Romosozumab 76
Table 36: Romosozumab SWOT Analysis, 2012 80
Table 37: Product Profile – Odanacatib 81
Table 38: Odanacatib SWOT Analysis, 2012 85
Table 39: Product Profile – BA-058 86
Table 40: BA-058 SWOT Analysis, 2012 89
Table 41: Product Profile – PTH(1-31)NH2 91
Table 42: PTH(1-31)NH2 SWOT Analysis, 2012 93
Table 43: Product Profile – Ostora 95
Table 44: Ostora SWOT Analysis, 2012 98
Table 45: UK Sales Forecasts ($m) for Osteoporosis, 2012-2022 102
Table 46: Key Events Impacting Sales for Osteoporosis in the UK, 2012–2022 104
Table 47: Osteoporosis Market – Drivers and Barriers in the United Kingdom, 2012–2022 104
Table 48: Key Launch Dates 118
Table 49: Key Patent Expiries 118
Table 50: Number of High-Prescribing Physicians Surveyed 125